Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPA1 | O60313 | 1/20 | 0.88 |
| ▸ | EIF5B | O60841 | 1/20 | 0.88 |
| ▸ | MET | P08581 | 1/20 | 0.88 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.88 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3689556 | 1.00 | OPA1 (0.88) | OPA1EIF5BMETHMOX2IDO1 | |
| SCHEMBL3689562 | 1.00 | OPA1 (0.88) | OPA1EIF5BMETHMOX2IDO1 | |
| SCHEMBL12449597 | 1.00 | OPA1 (0.88) | OPA1EIF5BMETHMOX2IDO1 | |
| SCHEMBL12808552 | 1.00 | OPA1 (0.88) | OPA1EIF5BMETHMOX2IDO1 | |
| SCHEMBL13241026 | 1.00 | OPA1 (0.88) | OPA1EIF5BMETHMOX2IDO1 | |
| Tivantinib SCHEMBL14865187 | 0.94 | OPA1 (1.00) | OPA1EIF5BMETHMOX2IDO1 | |
| Tivantinib SCHEMBL224883 | 0.94 | OPA1 (1.00) | OPA1EIF5BMETHMOX2IDO1 | |
| Tivantinib SCHEMBL1395795 | 0.94 | OPA1 (1.00) | OPA1EIF5BMETHMOX2IDO1 | |
| Tivantinib SCHEMBL44902 | 0.94 | OPA1 (1.00) | OPA1EIF5BMETHMOX2IDO1 | |
| Tivantinib SCHEMBL45306 | 0.94 | OPA1 (1.00) | OPA1EIF5BMETHMOX2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2392574-B1 | Indolyl pyrrolidines for the treatment of cancer | ARQULE INC (US) | 2013-12-18 | — | — | EP | claimed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | claimed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | claimed |
| EP-2392574-B1 | Indolyl pyrrolidines for the treatment of cancer | ARQULE INC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8513292-B2 | Compositions and methods for the treatment of cancer | ARQULE, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2392574-A1 | Indolyl pyrrolidines for the treatment of cancer | ArQule, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2173748-B1 | INDOLYL PYRROLIDINES FOR THE TREATMENT OF CANCER | ARQULE INC (US) | 2011-08-31 | — | — | EP | disclosed |
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | ARQULE, INC. (US) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183603-A1 | Compositions and Methods for the Treatment of Cancer | MKI67, POLI, DHPS | OPA1 225/4885EIF5B 175/4885MET 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.